Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 70/100

Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8

Thursday, January 5, 2023 2 min read
Key Takeaway: Co-Diagnostics, Inc. will be hosting a booth at CES 2023 from January 5-8 in Las Vegas. The company is set to exhibit its Co-Dx PCR at-home and point-of-care platform, which is undergoing final preparations for clinical evaluations. This platform is aimed for submission to the FDA for regulatory authorization. Interested attendees can visit Booth #8063 to learn more about Co-Diagnostics and its products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Co-Diagnostics is showcasing a novel PCR platform at CES 2023.
  • The platform is set to enter clinical evaluations, indicating positive progress.
  • The participation at a major event like CES highlights the company's growth potential.

Full Press Release Details

SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the 2023 Consumer Electronics Show (CES) this year from January 5-8 in Las Vegas, Nevada.
The Company will be exhibiting its upcoming Co-Dx PCR at-home and point-of-care platform, currently in the final stages of preparation for clinical evaluations prior to submission to the U.S. Food and Drug Administration for regulatory authorization. Attendees interested in learning more about the Company and its products are invited to visit Booth #8063 in the North Hall of the Las Vegas Convention Center.
The Co-Dx PCR platform is subject to FDA review and is not currently for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
SOURCE Co-Diagnostics

21 %

more press release views with

Frequently Asked Questions

What is Co-Diagnostics, Inc. known for?

Co-Diagnostics, Inc. specializes in developing molecular diagnostic tests.

Where will Co-Diagnostics exhibit its products?

They will exhibit at the 2023 CES in Las Vegas from January 5-8.

What product will Co-Diagnostics showcase at CES?

The upcoming Co-Dx PCR at-home and point-of-care platform.

Is the Co-Dx PCR platform available for sale?

No, the Co-Dx PCR platform is under FDA review and not for sale.

What technology does Co-Diagnostics use?

They use proprietary technology for testing nucleic acid molecules.

Tags: CODX Viatris Investor Conferences Healthcare Co-Diagnostics CES 2023 PCR platform FDA submission Las Vegas
Last updated: Jan 5, 2023